Arcus Biosciences RCUS Other collaboration — Total revenues

Other product segments

Similar metrics at other companies

BCRXCollaborative and other revenues — Total revenues

$2M+14.3%

EXELCollaboration — Total revenues

$55.84M+32.4%

CRNXCollaboration and license revenue — Total Revenue

$428K+18.6%

NBIXCollaboration revenues — Total revenues

$3.5M-60.7%

LLYCollaboration and Other Revenue — Revenue

$1.35B+19.4%

TARSLicense fees and collaboration revenue — Total revenues

$16.67M—

Questions, answered.

What is Arcus Biosciences's other collaboration — total revenues?

Arcus Biosciences (RCUS) reported other collaboration — total revenues of $5M in Q1 2026.

How has Arcus Biosciences's other collaboration — total revenues changed year-over-year?

Arcus Biosciences's other collaboration — total revenues decreased by 37.5% year-over-year, from $8M to $5M.

What is the long-term trend for Arcus Biosciences's other collaboration — total revenues?

Over 4 years (2021 to 2025), Arcus Biosciences's other collaboration — total revenues has grown at a -9.1% compound annual growth rate (CAGR), from $38M to $26M.

What does other collaboration — total revenues mean?

This metric represents the total revenue recognized from strategic partnerships, licensing agreements, or research collaborations that fall outside of the company's primary or core product revenue streams. It captures income generated through milestone payments, upfront fees, or cost-sharing arrangements associated with the development and commercialization of clinical-stage assets. Monitoring this figure helps investors assess the company's ability to monetize its R&D pipeline through external business development activities.